AQLANE Medical Product Theatre

Rethinking SUI treatment from a women’s perspective with Urolon®, the Bioresorbable Urethral Filler, Alex Lankhorst.

When rethinking SUI treatment from a women’s perspective, the preferred treatment option after PMFT should ideally be minimally-invasive, safe, effective and not placing any permanent materials in the body. Urolon®, a bioresorbable urethral filler, provides this option and closes the gap between conservative and surgical intervention, with a first choice treatment after pelvic floor muscle therapy. Urolon’s principle component are synthetic polycaprolactone (PCL) microspheres suspended in a carboxymethylcellulose (CMC) gel carrier. PCL is a well-known totally bioresorbable soft medical polymer and has been used in numerous CE marked and US FDA approved bioresorbable product applications for several decades and has demonstrated an excellent safety profile. PCL is bioresorbed through hydrolysis and fully excreted through normal metabolic pathways. This session will focus on the clinical data obtained in 2 recently published studies using this product for the treatment of female mild to moderate SUI, demonstrating an excellent safety profile combined with strong efficacy data and Quality of Life improvements up to 2 year follow-up.